A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab

Trial Profile

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Carotuximab (Primary) ; Bevacizumab
  • Indications Glioblastoma; Glioma; Gliosarcoma
  • Focus Therapeutic Use
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2016 Primary endpoint has been met. (Determine median overall survival (OS) in patients with recurrent or progressive GBM who have progressed on bevacizumab.), as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top